Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2013

01-10-2013 | Original Article

Frequency and Severity of Cirrhotic Cardiomyopathy and Its Possible Relationship with Bacterial Endotoxemia

Authors: Dimitrios S. Karagiannakis, Jiannis Vlachogiannakos, Georgios Anastasiadis, Irini Vafiadis-Zouboulis, Spiros D. Ladas

Published in: Digestive Diseases and Sciences | Issue 10/2013

Login to get access

Abstract

Background

The cardiac dysfunction presented in cirrhotic patients is already known as cirrhotic cardiomyopathy. The pathogenesis of this entity is not fully understood.

Aims

The aim of this study was to evaluate the frequency and characteristics of cirrhotic cardiomyopathy and to investigate the possible role of bacterial endotoxemia on its aggravation.

Methods

Forty-five cirrhotics were studied by a tissue Doppler imaging echocardiography at rest and after stress. The diagnosis of left ventricular diastolic dysfunction was based on the latest guidelines of the American Society of Echocardiography, whereas its severity was defined by the E/e’av ratio. Endotoxemia was estimated by measuring the serum levels of lipopolysaccharide-binding protein (LBP) and cytokines.

Results

None of the patients had systolic dysfunction, but 17/45 (37.8 %) had a diastolic one. Patients with grade II diastolic dysfunction had significantly longer QTc (p = 0.049), larger left atrium volume (p = 0.013), higher Brain Natriuretic Peptide levels (p = 0.007) and higher LBP levels (p = 0.02), compared to those with normal cardiac function, without differences in the systemic hemodynamics and the cytokines’ levels. Moreover, the severity of diastolic dysfunction as reflected by the E/e’av. was significantly correlated with the LBP levels (p = 0.002). On the multivariate analysis, the LBP was independently associated with the presence of diastolic dysfunction.

Conclusions

Cirrhosis is commonly complicated by cardiac dysfunction. Patients with severe cirrhotic cardiomyopathy have higher LBP levels, which are significantly correlated with the degree of diastolic dysfunction. Our findings support a potential role of bacterial endotoxemia on the aggravation of cardiomyopathy in cirrhotic patients.
Literature
1.
go back to reference Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rode’s J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;5:1151–1157.CrossRef Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rode’s J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;5:1151–1157.CrossRef
2.
go back to reference Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:S121–S131.PubMedCrossRef Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:S121–S131.PubMedCrossRef
3.
4.
go back to reference Bellot P, Garcia-Pagan JC, France’s R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;5:2044–2052.CrossRef Bellot P, Garcia-Pagan JC, France’s R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;5:2044–2052.CrossRef
5.
go back to reference Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29:992–999.PubMedCrossRef Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29:992–999.PubMedCrossRef
7.
8.
go back to reference Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol. 2006;44:994–1002.PubMedCrossRef Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol. 2006;44:994–1002.PubMedCrossRef
9.
go back to reference Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology. 1996;110:1191–1198.PubMedCrossRef Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology. 1996;110:1191–1198.PubMedCrossRef
10.
go back to reference Ma Z, Meddings JB, Lee SS. Membrane physical properties determine β-adrenergic receptor function in cirrhotic rats. Am J Physiol. 1994;267:G87–G93.PubMed Ma Z, Meddings JB, Lee SS. Membrane physical properties determine β-adrenergic receptor function in cirrhotic rats. Am J Physiol. 1994;267:G87–G93.PubMed
11.
go back to reference Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol. 2005;146:315–323.PubMedCrossRef Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol. 2005;146:315–323.PubMedCrossRef
12.
go back to reference Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology. 2000;118:937–944.PubMedCrossRef Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology. 2000;118:937–944.PubMedCrossRef
13.
go back to reference Kleber G, Braillon A, Gaudin C, Champigneulle B, Cailmail S, Lebrec D. Hemodynamic effects of endotoxin and platelet activating factor in cirrhotic rats. Gastroenterology. 1992;103:282–288.PubMed Kleber G, Braillon A, Gaudin C, Champigneulle B, Cailmail S, Lebrec D. Hemodynamic effects of endotoxin and platelet activating factor in cirrhotic rats. Gastroenterology. 1992;103:282–288.PubMed
14.
go back to reference Guilo P, Mansourati J, Maheu B, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol. 1997;79:1276–1278.CrossRef Guilo P, Mansourati J, Maheu B, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol. 1997;79:1276–1278.CrossRef
15.
go back to reference Perez-Paramo M, Munoj J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000;31:43–48.PubMedCrossRef Perez-Paramo M, Munoj J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000;31:43–48.PubMedCrossRef
16.
go back to reference Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107–133.PubMedCrossRef Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107–133.PubMedCrossRef
17.
go back to reference Achecar L, Gonzalez-Tallon A, Mesonero F, Serradilla R, Milicua JM, Ruiz-del-Arbol L. Relationship between circulatory dysfunction and severity of cardiomyopathy in patients with cirrhosis. J Hepatol. 2011;54:S61–S62.CrossRef Achecar L, Gonzalez-Tallon A, Mesonero F, Serradilla R, Milicua JM, Ruiz-del-Arbol L. Relationship between circulatory dysfunction and severity of cardiomyopathy in patients with cirrhosis. J Hepatol. 2011;54:S61–S62.CrossRef
18.
go back to reference Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–110.PubMedCrossRef Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–110.PubMedCrossRef
19.
go back to reference Nazar A, Sitges M, Guevara M, et al. Cardiomyopathy in patients with cirrhosis. Frequency, characteristics and relationship with circulatory dysfunction and prognosis. J Hepatol. 2010;53:S85. Nazar A, Sitges M, Guevara M, et al. Cardiomyopathy in patients with cirrhosis. Frequency, characteristics and relationship with circulatory dysfunction and prognosis. J Hepatol. 2010;53:S85.
20.
go back to reference Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998;27:28–34.PubMedCrossRef Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998;27:28–34.PubMedCrossRef
21.
go back to reference Henriksen JH, Goetze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;52:1511–1517.PubMedCrossRef Henriksen JH, Goetze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;52:1511–1517.PubMedCrossRef
22.
go back to reference Albillos A, De La Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37:208–217.PubMedCrossRef Albillos A, De La Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37:208–217.PubMedCrossRef
23.
go back to reference Rozenberg S, Besse S, Brisson H, et al. Endotoxin-induced myocardial dysfunction in senescent rats. Crit Care. 2006;10:R124.PubMedCrossRef Rozenberg S, Besse S, Brisson H, et al. Endotoxin-induced myocardial dysfunction in senescent rats. Crit Care. 2006;10:R124.PubMedCrossRef
24.
25.
go back to reference Opal SM, Scannon PJ, Vincent JL, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;180:1584–1589.PubMedCrossRef Opal SM, Scannon PJ, Vincent JL, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;180:1584–1589.PubMedCrossRef
26.
go back to reference Krag A, Bendtsen F, Kjaer A, Leth-Petersen C, Moller S. Cardiac function studied by dobutamine stress MRI in patients with mild cirrhosis. J Hepatol. 2009;50:S277.CrossRef Krag A, Bendtsen F, Kjaer A, Leth-Petersen C, Moller S. Cardiac function studied by dobutamine stress MRI in patients with mild cirrhosis. J Hepatol. 2009;50:S277.CrossRef
27.
go back to reference Klein AL, Burstow DJ, Talik AJ, Zachariak PK, Bailey KR, Seward JB. Effects of age on left ventricular dimensions and filling dynamics in 117 normal persons. Mayo Clin Proc. 1994;69:212–224.PubMedCrossRef Klein AL, Burstow DJ, Talik AJ, Zachariak PK, Bailey KR, Seward JB. Effects of age on left ventricular dimensions and filling dynamics in 117 normal persons. Mayo Clin Proc. 1994;69:212–224.PubMedCrossRef
28.
go back to reference Wong F, Villamil A, Merli M, et al. Prevalence of diastolic dysfunction in cirrhosis, and its clinical significance. Hepatology. 2011;54:475A–476A.CrossRef Wong F, Villamil A, Merli M, et al. Prevalence of diastolic dysfunction in cirrhosis, and its clinical significance. Hepatology. 2011;54:475A–476A.CrossRef
29.
go back to reference Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau JM, Mont L, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 1989;320:409–415.PubMedCrossRef Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau JM, Mont L, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 1989;320:409–415.PubMedCrossRef
30.
go back to reference Preedy VR, Siddiq T, Why H, Richardson PJ. The deleterious effects of alcohol on the heart: involvement of protein turnover. Alcohol Alcohol. 1994;29:141–147.PubMed Preedy VR, Siddiq T, Why H, Richardson PJ. The deleterious effects of alcohol on the heart: involvement of protein turnover. Alcohol Alcohol. 1994;29:141–147.PubMed
31.
go back to reference Harcombe AA, Ramsay L, Kenna JG, et al. Circulation antibodies to cardiac protein-acetaldehyde adducts in alcoholic heart muscle disease. Clin Sci. 1995;88:262–268. Harcombe AA, Ramsay L, Kenna JG, et al. Circulation antibodies to cardiac protein-acetaldehyde adducts in alcoholic heart muscle disease. Clin Sci. 1995;88:262–268.
32.
go back to reference Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology. 1997;26:1131–1137.PubMed Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology. 1997;26:1131–1137.PubMed
33.
go back to reference Grose RD, Nolan J, Dillon JF, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol. 1995;22:326–332.PubMedCrossRef Grose RD, Nolan J, Dillon JF, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol. 1995;22:326–332.PubMedCrossRef
Metadata
Title
Frequency and Severity of Cirrhotic Cardiomyopathy and Its Possible Relationship with Bacterial Endotoxemia
Authors
Dimitrios S. Karagiannakis
Jiannis Vlachogiannakos
Georgios Anastasiadis
Irini Vafiadis-Zouboulis
Spiros D. Ladas
Publication date
01-10-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2693-y

Other articles of this Issue 10/2013

Digestive Diseases and Sciences 10/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine